Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Latest Press Releases

Latest Press Releases

A Nurse examines medications in the storeroom at the TB Practecal Warehouse in Nukus, Uzbekistan. Photograph by Amelia Freelander
Press release
Press release |
03 May 2022
Tuberculosis

MSF responds to new WHO guidance recommending vastly shorter, improved and better-tolerated treatment for multidrug-resistant TB

5 min
On November 10, MSF held a demonstration in front of the White House in Washington, DC, calling on the Biden administration—which gave pharmaceutical corporations billions of US taxpayer dollars to develop COVID-19 vaccines—to do more to ensure global vaccine equity. Photograph by Christopher Lee
Press release
Press release |
27 April 2022
COVID-19

MSF calls on Moderna to transfer mRNA vaccine technology without further delay

4 min
Vials of liposomal amphotericin B (L-AmB) Photo credit: Albert Masias/MSF
Press release
Press release |
20 April 2022
HIV/AIDS

MSF responds to new simplified WHO treatment guidelines for cryptococcal meningitis, the number two killer of people living with HIV/AIDS

7 min
Nursing assistant of MSF ambulance service disinfects equipment after an intervention in the city of Soyapango. Photograph by Alejandra Sandoval
Press release
Press release |
04 April 2022
COVID-19

MSF urges governments to reject the draft COVID-19 text at WTO that would set a negative precedent

4 min
Muhammad Yusuf (8) is undergoing a sputum induction in a specialized room in Paediatric TB hospital in Dushanbe. Analysing sputum culture is considered the best way to diagnose TB. However, children have great difficulty in producing it themselves. Photograph by Jasňa Riegerová
Press release
Press release |
21 March 2022
Tuberculosis

MSF responds to updated WHO guidelines for tuberculosis in children

3 min
An MSF doctor taking the medical history of someone coming for their COVID-19 vaccination. They check if he has any symptoms of COVID, or is currently taking any medication. Photograph by Pirah Qasi
Press release
Press release |
17 March 2022
COVID-19

MSF responds to Medicines Patent Pool deal with 35 manufacturers to produce COVID-19 treatment nirmatrelvir/ritonavir

3 min
This patient is a 46-year-old male farmer tested positive for COVID-19. He had difficulty breathing and needed oxygen support and intravenous fluids. Upon arrival at the Surigao City pier, an ambulance picked him up and brought him to Caraga Regional Hospital. Photograph by Regina Layug Rosero
Press release
Press release |
16 March 2022
COVID-19

MSF responds to potential compromise on the ‘TRIPS Waiver‘

4 min
A clinician gathering antiretroviral medications for a patient at Maram Dispensary in Ndhiwa sub county, Homa Bay County, Kenya, 2021 Photo credit: Njiiri Karago/MSF
Press release
Press release |
04 March 2022
HIV/AIDS

ViiV will not license new game-changing long-acting HIV prevention drug to generic manufacturers

3 min
  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury